OM
MLYS icon

Opaleye Management’s Mineralys Therapeutics MLYS Stock Holding History

Opaleye Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-115,000
Closed -$1.8M – 49
2023
Q1 		$1.8M Buy
+115,000
New +$1.94M 0.54% 36

Other funds holding MLYS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Opaleye Management's MLYS Position: Q2 2023 in Review

Opaleye Management sold out of Mineralys Therapeutics (MLYS) in Q2 2023, closing a stake of 115,000 shares — an estimated $1.8M sold.

Opaleye Management first reported a position in MLYS in Q1 2023 and held it in 1 quarter. The position peaked at $1.8M in Q1 2023. 68 funds tracked by Wall St. Rank hold MLYS as of Q2 2023.

  • Opaleye Management reported no remaining Mineralys Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Opaleye Management sold 115,000 Mineralys Therapeutics shares in Q2 2023, an estimated $1.8M.
  • Opaleye Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 1 quarter.
  • Opaleye Management's Mineralys Therapeutics position peaked at $1.8M in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2023.

Based on Opaleye Management's 13F filing for Q2 2023, filed 14 Aug 2023.